Skip to content

LBRX LBRX Free cash flow

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
-$51.2M
Alto Neuroscience logo
Alto NeuroscienceANRO
-$27.65M-66.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$6.11M+173%
Opko Health logo
Opko HealthOPK
-$21.14M+44.0%
Alkermes logo
AlkermesALKS

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Calculated from LBRX’s reported figures.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's free cash flow?
LBRX (LBRX) reported free cash flow of -$23.32M in Q1 2026.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.